June 13, 2022 -- Specifica and Sanofi have reached an agreement under which Specifica’s Generation 3 Antibody Discovery Platform will be transferred enabling the integration into Sanofi’s antibody discovery programs.
Specifica's Gen 3 discovery platform yields a broad diversity of specific and developable antibodies with very high affinities, thereby avoiding downstream hit-to-lead optimization bottlenecks such as affinity maturation and developability optimization, according to the company.
The Gen 3 libraries combine clinically validated antibody frameworks with compatible binding loop sequences from natural human antibodies that have been purged of sequence-based developability liabilities.
Specifica CEO Ken Sharples in a statement said the partnership with Sanofi will provide a "complete antibody discovery platform through a combination of Gen 3 libraries, antibody optimization solutions, and integrated discovery tools."
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
